Amarin Corporation plc (AMRN)
NASDAQ: AMRN · Real-Time Price · USD
10.42
+0.01 (0.10%)
At close: May 12, 2025, 4:00 PM
10.49
+0.07 (0.67%)
After-hours: May 12, 2025, 6:16 PM EDT
Amarin Corporation Revenue
Amarin Corporation had revenue of $42.02M in the quarter ending March 31, 2025, a decrease of -25.66%. This brings the company's revenue in the last twelve months to $214.11M, down -22.83% year-over-year. In the year 2024, Amarin Corporation had annual revenue of $228.61M, down -25.51%.
Revenue (ttm)
$214.11M
Revenue Growth
-22.83%
P/S Ratio
1.00
Revenue / Employee
$778,589
Employees
275
Market Cap
215.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 228.61M | -78.30M | -25.51% |
| Dec 31, 2023 | 306.91M | -62.28M | -16.87% |
| Dec 31, 2022 | 369.19M | -213.99M | -36.69% |
| Dec 31, 2021 | 583.19M | -30.87M | -5.03% |
| Dec 31, 2020 | 614.06M | 184.31M | 42.89% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
AMRN News
- 5 days ago - Amarin Corporation plc (AMRN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire
- 14 days ago - Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - GlobeNewsWire
- 4 weeks ago - Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday - Benzinga
- 4 weeks ago - Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change - GlobeNewsWire
- 5 weeks ago - Amarin Appoints JEC Capital Partners' Michael Torok to Board of Directors - GlobeNewsWire
- 7 weeks ago - Concerned Shareholder Group Urges Amarin's Board of Directors to Initiate a Strategic Review Following Two Years of Underperformance - Business Wire
- 7 weeks ago - New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo - GlobeNewsWire